Vitreoretinopathy: Sequencing Panel

Test Code: MM238  
Turnaround time: 6 weeks  
CPT Codes: 81404 x1, 81406 x1, 81479 x1

Condition Description

Vitreoretinopathy is a general term used to describe retinal disease that also affects the vitreous body. Several types of vitreoretinopathies exist giving rise to a spectrum of phenotypic presentations such as retinal detachment (or traction), optically empty vitreous, fibrillary condensation, cataract, and neovascularization. The condition includes, but is not limited to, familial exudative vitreoretinopathy, Norrie disease, Wagner syndrome, snowflake vitreoretinal degeneration, Stickler syndrome and retinal vasculopathy with cerebral leukodystrophy. The vitreoretinopathies may be inherited in an autosomal dominant, autosomal recessive or X-linked manner (complex inheritance has also been suggested).

References:

- OMIM
- GeneReviews

Genes

COL11A1, COL2A1, COL9A1, FZD4, KCNJ13, LRP5, NDP, TSPAN12, VCAN

Indications

This test is indicated for:

- Confirmation of a clinical diagnosis of vitreoretinopathy.
- Carrier testing in adults with a family history of vitreoretinopathy.

Methodology

Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

Detection

Clinical Sensitivity: Unknown. Pathogenic variants in the promoter region, some pathogenic variants in the introns and other regulatory elements of unknown pathogenic variants cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical and/or biochemical phenotype.

Analytical Sensitivity: ~99%.

Specimen Requirements

Submit only 1 of the following specimen types

Type: Whole Blood

Specimen Requirements:

In EDTA (purple top) tube:
Infants (2 years): 3-5 ml  
Older Children & Adults: 5-10 ml.

Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.

Type: Isolated DNA

Specimen Requirements:

In microtainer: 60 ug  
Isolation using the Qiagen™ Puregene kit for DNA extraction is recommended.
Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.

**Special Instructions**

Please include fundus photographs, electroretinogram (ERG) findings, visual field findings, and visual acuity, if available, for expert review and clinical correlation with test results.

**Related Tests**

- Eye Disorders: Comprehensive Sequencing and Deletion/Duplication Panels.
- Vitreoretinopathy: Deletion/Duplication Panel.